Trader consensus strongly favors no hantavirus vaccine reaching approval or availability by the end of 2026, reflecting the early preclinical and initial clinical stages of leading candidates. Research by teams at the U.S. Army Medical Research Institute of Infectious Diseases and the University of Bath has produced DNA and mRNA approaches that generate neutralizing antibodies in small human or animal studies, yet these remain years from Phase 2 or 3 trials without accelerated federal funding comparable to Operation Warp Speed. Recent 2026 cruise-ship clusters have heightened surveillance by agencies like the CDC and WHO, but sporadic case counts and modest efficacy data from existing Asian vaccines underscore the timeline barriers. An unexpected large-scale investment or rapid regulatory pathway could shift odds, though current model projections and development pipelines indicate such acceleration remains unlikely within the year.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · DiperbaruiHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$91,897 Vol.
$91,897 Vol.
Dec 31, 2026
$91,897 Vol.
$91,897 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus strongly favors no hantavirus vaccine reaching approval or availability by the end of 2026, reflecting the early preclinical and initial clinical stages of leading candidates. Research by teams at the U.S. Army Medical Research Institute of Infectious Diseases and the University of Bath has produced DNA and mRNA approaches that generate neutralizing antibodies in small human or animal studies, yet these remain years from Phase 2 or 3 trials without accelerated federal funding comparable to Operation Warp Speed. Recent 2026 cruise-ship clusters have heightened surveillance by agencies like the CDC and WHO, but sporadic case counts and modest efficacy data from existing Asian vaccines underscore the timeline barriers. An unexpected large-scale investment or rapid regulatory pathway could shift odds, though current model projections and development pipelines indicate such acceleration remains unlikely within the year.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Pasar Dibuka: May 4, 2026, 10:39 AM ET
Volume
$91,897Tanggal Berakhir
Dec 31, 2026Pasar Dibuka
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus strongly favors no hantavirus vaccine reaching approval or availability by the end of 2026, reflecting the early preclinical and initial clinical stages of leading candidates. Research by teams at the U.S. Army Medical Research Institute of Infectious Diseases and the University of Bath has produced DNA and mRNA approaches that generate neutralizing antibodies in small human or animal studies, yet these remain years from Phase 2 or 3 trials without accelerated federal funding comparable to Operation Warp Speed. Recent 2026 cruise-ship clusters have heightened surveillance by agencies like the CDC and WHO, but sporadic case counts and modest efficacy data from existing Asian vaccines underscore the timeline barriers. An unexpected large-scale investment or rapid regulatory pathway could shift odds, though current model projections and development pipelines indicate such acceleration remains unlikely within the year.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$91,897Tanggal Berakhir
Dec 31, 2026Pasar Dibuka
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus strongly favors no hantavirus vaccine reaching approval or availability by the end of 2026, reflecting the early preclinical and initial clinical stages of leading candidates. Research by teams at the U.S. Army Medical Research Institute of Infectious Diseases and the University of Bath has produced DNA and mRNA approaches that generate neutralizing antibodies in small human or animal studies, yet these remain years from Phase 2 or 3 trials without accelerated federal funding comparable to Operation Warp Speed. Recent 2026 cruise-ship clusters have heightened surveillance by agencies like the CDC and WHO, but sporadic case counts and modest efficacy data from existing Asian vaccines underscore the timeline barriers. An unexpected large-scale investment or rapid regulatory pathway could shift odds, though current model projections and development pipelines indicate such acceleration remains unlikely within the year.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan